All In Biotech

NDA 214120 · Bristol

Onureg

Azacitidine · Oral · Nucleoside Metabolic Inhibitor

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Sep 1, 2020

Approved uses

2

Original approval plus efficacy supplements

Registered trials

1,227

154 Phase 3, 243 recruiting

FAERS reports

19,441

18,487 serious, 6,234 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 12, 2026.

ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. ONUREG is a nucleoside metabolic inhibitor indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy ( 1 ).

Mechanism: Azacitidine is a pyrimidine nucleoside analog of cytidine that inhibits DNA/RNA methyltransferases. Azacitidine is incorporated into DNA and RNA following cellular uptake and enzymatic biotransformation to nucleotide triphosphates. Incorporation of azacitidine into the DNA of cancer cells in vitro, including acute myeloid leukemia cells, inhibited DNA methyltransferases, reduced DNA methylation and altered gene expression, including re-expression of genes regulating tumor suppression and cell differentiation. Incorporation of azacitidine into the RNA of cancer cells, including leukemic cells,...

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 9, 2026 Supplement 3 · Efficacy OrphanLetterLabel
  • Sep 1, 2020 Original approval · Type 3 - New Dosage Form · priority review OrphanLabelLetterReview
2 products under this application
  • ONUREG · AZACITIDINE 200MG · TABLET, ORAL · Prescription
  • ONUREG · AZACITIDINE 300MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Azacitidine" as an intervention, any sponsor and status, largest first.

All 1,227 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • febrile neutropenia2,064
  • death1,974
  • off label use1,760
  • myelosuppression1,700
  • neutropenia1,480
  • acute myeloid leukaemia1,334
  • pneumonia1,096
  • thrombocytopenia1,084
  • pyrexia1,047
  • drug ineffective1,039
  • anaemia889
  • infection715

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20053
20061
20075
200816
200943
201086
2011119
201291
201378
2014278
2015404
2016322
2017670
2018754
2019942
20201,167
20212,108
20222,812
20232,617
20242,512
20252,648
20261,764

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Onureg (Azacitidine)

2024 spending

$85.9M

Beneficiaries

665

3,700 claims

Per beneficiary

$129,238

$1,779.43 per unit

View as table
YearSpending
2020$4,683,188
2021$42,562,265
2022$60,141,759
2023$68,778,094
2024$85,943,002

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 431 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.